FDA Clears Path for Cheaper Heparin Generics to Hit Market
Published Date: 8/4/2025
Notice
Summary
The FDA says three types of heparin sodium injectable drugs weren’t pulled from the market because of safety or effectiveness problems. This means generic drug makers can now get approval to make and sell their versions, helping keep medicine options open and possibly prices down. Patients and healthcare providers can keep trusting these medicines without worry.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Enables ANDA Approvals Referencing These Heparins
Because of that finding, the FDA can approve abbreviated new drug applications (ANDAs) that refer to these three heparin sodium products under NDA 019042, provided all other legal and regulatory requirements are met. That allows companies seeking generic approval to use these reference products in their ANDA submissions.
FDA Finds Three Heparin Products Intact
The FDA determined that three heparin sodium injectable products under NDA 019042 were not withdrawn from sale for reasons of safety or effectiveness. The products named include: heparin sodium 1,000 units in sodium chloride 0.9% in plastic container (injectable, 200 units/100 mL), heparin sodium 2,000 units in sodium chloride 0.9% in plastic container (injectable, 200 units/100 mL), and heparin sodium 5,000 units in sodium chloride 0.9% in plastic container (injectable, 1,000 units/100 mL).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
Previous / Next Documents
Previous: 2025-14686 — Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, S/V MORNING STAR
The Maritime Administration is checking if a foreign-built small passenger boat, the S/V MORNING STAR, can be used for trips along the U.S. coast. They want to make sure this won’t hurt American boat builders or businesses using U.S.-made vessels. If you’re involved in coastal boat trade, now’s the time to share your thoughts before a decision is made!
Next: 2025-14693 — Combined Notice of Filings
Several natural gas pipeline companies have filed requests to change their rates and agreements starting September 1, 2025. These updates could affect customers and partners by adjusting prices or contract terms. If you want to speak up or get involved, you have until August 11, 2025, at 5 p.m. ET to comment or protest.